JACOBS-HOLDING-AG
17.4.2024 11:06:32 CEST | Business Wire | Press release
Jacobs Holding today announced that the board of directors has appointed Timothy Franks as Chief Executive Officer effective May 1, 2024.
With an impressive 25-year career at two prominent investment firms, Tim brings extensive experience and a proven track record in global private equity. His most recent role was as a Partner and Co-CEO of the democratized private equity business at KKR. He played a pivotal role in building KKR’s European franchise, leading the EMEA Core strategy, and overseeing the development of activities in the UK & Ireland, as well as the Consumer industry team in EMEA. Prior to that, Tim spent 17 years at Advent International, where he notably opened and led the New York office from 2010 to 2013. Throughout his tenure at both firms, he held various chair and board positions at portfolio companies.
Under his leadership, Jacobs Holding aims at further strengthening its investment activities, particularly in the services, healthcare and consumer industries. Tim’s strong investment focus on helping businesses with their sustainability and digitalization goals will be pivotal for Jacobs Holding in consolidating its investment approach, and investing in the growth potential of existing and future portfolio companies.
Nicolas and Philippe Jacobs, Co-Chairmen commented: “We are excited to have Tim join Jacobs Holding. Beyond being a highly accomplished private equity manager with an impressive track record, he has proven himself as a strong leader. Tim possesses all the qualities needed to get Jacobs Holding to the next level as a sustainable and entrepreneurial investor.”
Timothy Franks commented: “I look forward to working with the Jacobs team. It will be a real privilege to lead Jacobs Holding, given the strong purpose of the firm and its investment approach, which intersects three investment trends in alternative asset management: focusing on direct investments, pursuing a long-term investment horizon, and bringing sustainability and digitalization to the core of its activities.”
About Jacobs Holding AG
Jacobs Holding is a global professional investment firm founded by late entrepreneur Klaus J. Jacobs, in which he bundled his entrepreneurial activities in 1994. Jacobs Holding invests with a long-term horizon in companies active in non-cyclical businesses which already have or aim for a leading market position and have further growth and value creation potential. The current portfolio of Jacobs Holding consists of Cognita (www.cognita.com), Colosseum Dental Group (www.colosseumdental.com), North American Dental Group (www.nadentalgroup.com) as well as a large stake in the publicly traded company Barry Callebaut AG (www.barry-callebaut.com). The sole economic beneficiary of Jacobs Holding is the Jacobs Foundation, one of the world's leading charitable foundations for the promotion of development opportunities for children and young people. Since the foundation was established in 1989, around CHF 800 million has been paid out cumulatively.
Additional features:
File: JAG_CEO_English
File: Picture Timothy Franks
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240417007318/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Arboris Capital Selects ROYC to Expand Private Markets Capabilities on CapGain Platform18.5.2026 09:00:00 CEST | Press release
Arboris Capital Limited (“Arboris”), a DIFC-based firm arranging alternative investments, authorised by the Dubai Financial Services Authority (DFSA), today announced that it has selected ROYC AB (“ROYC”), a private markets technology and infrastructure provider, to support the continued development of its private markets offering through its platform, CapGain. In its ongoing efforts to expand its private markets capabilities across the Middle East, Arboris has undertaken a strategic review of how to further scale its offering while maintaining the integrity of its existing platform. As a result, Arboris has chosen to integrate ROYC’s fund access, sourcing, and structuring capabilities into CapGain, complementing its existing infrastructure. CapGain is Arboris’s proprietary investment platform, purpose-built to facilitate access between international private market opportunities and Professional Investors in the region. CapGain provides fully digital investor onboarding and KYC, a secu
OdysseyRe Announces New Co-Chief Underwriting Officers for EMEA18.5.2026 09:00:00 CEST | Press release
Odyssey Reinsurance Company (OdysseyRe) today announced the appointments of Tegwen Gromellon and Anne-Claire Serres as co-chief underwriting officers of its EMEA division, effective July 1. They succeed longtime Chief Underwriting Officer, Gaël Le Païh, who is retiring later this year following 36 years with the Company. Based in Paris, Serres joined OdysseyRe in 2018 as the market director for France and will lead the division’s business across France, Africa and the Middle East. Gromellon, who joined OdysseyRe in 2004, has served as market director for Germany, Austria, Benelux and Switzerland since 2019. He will take the lead for the rest of Europe, including the relationship with the Company’s representative office in Stockholm for the Nordic markets and across Turkey. “We are delighted to appoint both Tegwen and Anne-Claire to these important leadership positions,” said Isabelle Dubots-Lafitte, chief executive officer of EMEA for OdysseyRe. “These appointments recognize their sign
LogicMonitor and Deutsche Telekom Expand Partnership Across Europe18.5.2026 09:00:00 CEST | Press release
Expanded availability of LogicMonitor within Deutsche Telekom’s managed services portfolio follows successful operational use in the UKSelect outcomes include reduced reporting times and proactive incident preventionExpansion extends across DACH, Benelux, and the Nordics LogicMonitor®, the AI-first platform for Autonomous IT, today announced the expanded availability of its platform within Deutsche Telekom’s managed services portfolio across selected European markets, including DACH, Benelux, and the Nordics. The expansion builds on operational use of LogicMonitor in the United Kingdom since 2023, where it has supported Deutsche Telekom’s service teams in improving visibility across network, cloud, and hybrid infrastructure environments. Experience gained from these deployments is now informing broader service enablement across additional European markets. As enterprise IT environments grow more complex, organisations require more than visibility—they need predictive resilience. Throug
Prokarium Reports Positive Interim Data from Phase 1/1b PARADIGM-1 trial of ZH9 in NMIBC patients, Demonstrating Excellent Safety and Encouraging Early Efficacy18.5.2026 09:00:00 CEST | Press release
ZH9 is very well tolerated with a favourable safety profile, and no dose-limiting toxicities or Grade ≥3 drug-related adverse events reported.ZH9 demonstrates 91% freedom-from-relapse in NMIBC patients who have reached study end.Company plans to run a larger phase 2 study across a range of patient populations spanning intermediate risk and high risk including CIS. Prokarium, a clinical-stage biopharmaceutical company pioneering bacterial immunotherapies for the treatment of solid tumours, today announced safety and antitumour efficacy results from an interim review of the ongoing Phase 1/1b PARADIGM-1 trial of ZH9 in non-muscle invasive bladder cancer (NMIBC) patients. These data were shared via an oral podium presentation at the American Urology Association (AUA26) Annual Meeting. Prokarium CMO, Dr Josefin-Beate Holz said “These data demonstrate ZH9 as a universally applicable treatment for patients. As the treatment is very well tolerated and is showing impactful outcomes for early a
VahatiCor Appoints Harry D. Rowland, Ph.D., as Chief Executive Officer18.5.2026 08:00:00 CEST | Press release
Endotronix co-founder and former CEO joins VahatiCor as the company advances the A-FLUX Reducer System® and the SERRA-I early feasibility study VahatiCor, Inc., a medtech company developing interventional therapies for Coronary Microvascular Dysfunction (CMD), announced today the appointment of Harry D. Rowland, Ph.D., as Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260517830314/en/ VahatiCor CEO, Harry D. Rowland, Ph.D. Rowland previously served as Chief Executive Officer and President of Endotronix, where he led the development and commercialization of the Cordella™ Pulmonary Artery Sensor and Heart Failure System. Under his leadership, Endotronix raised over $150 million and grew to more than 150 employees. He also oversaw the PROACTIVE-HF pivotal trial from execution through FDA premarket approval and commercial launch. Following its acquisition by Edwards Lifesciences in 2024, Rowland stayed o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom